Innovative End Period Cash Flow from 2010 to 2024

002173 Stock   8.09  0.55  6.37%   
Innovative Medical's End Period Cash Flow is decreasing over the years with slightly volatile fluctuation. Overall, End Period Cash Flow is expected to go to about 482.6 M this year. From 2010 to 2024 Innovative Medical End Period Cash Flow quarterly data regression line had arithmetic mean of  887,651,160 and r-squared of  0.75. View All Fundamentals
 
End Period Cash Flow  
First Reported
2019-09-30
Previous Quarter
530 M
Current Value
196 M
Quarterly Volatility
229.7 M
 
Covid
Check Innovative Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Innovative Medical's main balance sheet or income statement drivers, such as Interest Expense of 4.2 M, Selling General Administrative of 40.6 M or Total Revenue of 550.5 M, as well as many indicators such as . Innovative financial statements analysis is a perfect complement when working with Innovative Medical Valuation or Volatility modules.
  
This module can also supplement various Innovative Medical Technical models . Check out the analysis of Innovative Medical Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Innovative Stock

Innovative Medical financial ratios help investors to determine whether Innovative Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Innovative with respect to the benefits of owning Innovative Medical security.